Richard Proehl becomes vp of manufacturing at CML

Has spent more than 30 years in API manufacturing

Cambridge Major Laboratories (CML), a US producer of pharmaceutical intermediates and APIs, has welcomed Richard Proehl as vice president of manufacturing.

Proehl will be responsible for all plant scale manufacturing operations within the organisation, as well as all engineering and EHS functions. He brings more than 30 years of API manufacturing experience to the firm, based in Germantown, WI and has a strong focus on EHS and Quality Compliance.

‘Rick brings a wealth of experience to our team and his focus on quality and execution is a great fit with our company values,’ said Brian Scanlan, president and ceo of CML.

Prior to joining CML, Proehl was the St Louis site director for Covidien, where he was responsible for the company's largest API plant of about 900 employees.

‘The company's growth has been impressive and I will drive operational discipline in our manufacturing systems as we build on our strong fundamental capabilities and provide our customers with world class API manufacturing operations,’ said Proehl.

You may also like

Manufacturing

Cambridge Major Labs supports Summit antibiotic project

The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Manufacturing

API launch from new Cambridge Major Laboratories facility

This is the first commercial launch of an active pharmaceutical ingredient from its newest facility
Ingredients

AAIPharma Charleston sterile manufacturing receives MHRA approval

<p>International pharmaceutical services provider AAIPharma's sterile manufacturing plant in Charleston, South Carolina, US, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilised products.</p>
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Ingredients

Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing

The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
Ingredients

Therapeutic: vimseltinib for tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a rare, non-malignant tumour that results from a translocation in the colony stimulating factor 1 (CSF1) gene
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Subscribe now